Monoclonal antibody therapy Archives

Trastuzumab-based therapeutics: Choosing the appropriate species for safety studies

Written by

Dr Gail Lewis Phillips researches trastuzumab based therapies and argues that rodents are not the best choice for safety studies as the equivalent antigen (neu) does not bind

Trastuzumab is a clinically approved monoclonal antibody therapy which targets HER2 (or ErbB2) for treatment of HER2-overexpressing breast and gastric cancers. Safety studies are important in the development of antibody therapeutics and should use animal species which bind the target antigen (HER2) to understand target-mediated effects, in addition to a non-binding species to observe non-targeted effects. It is acknowledged that […]

Is monoclonal antibody therapy effective and achievable in hospitals with limited resources?

Written by

Dr Nikhitha Mantri researched the use of MAT treatments for COVID-19 patients with mild to moderate symptoms at an inner-city hospital with limited resources in the Bronx

Monoclonal antibody therapy (MAT) is a way of treating COVID-19 for people who have tested positive, have mild to moderate symptoms, and are at high risk of developing more serious symptoms and complications. Although there are already studies showing promising results, the number of patients in the US, especially ethnic minorities, who have so far received MAT is small. Dr […]